Description: Hikma Pharmaceuticals Plc is a pharmaceutical company. The Company develops, manufactures and markets a range of branded and non-branded generic pharmaceutical products in solid, semi-solid, liquid and injectable final dosage forms, across the United States, the Middle East and North Africa (MENA) region and Europe. The Company's segments include Branded, Injectables, Generics and Others. The Branded business sells branded generics and in-licensed products across the MENA region and other markets. The Injectables business sells specialized generic injectable products across the globe. The Generics business sells non-injectable generic products in the United States. The Branded business has approximately 380 products in over 1,120 dosage forms and strengths. Its products include Amoclan, Blopress, Omnicef, Prograf and Suprax. The Injectables business' products include Argatroban, Fentanyl, Glycopyrrolate, Nicardipine and Phenylephrine.
Home Page: www.hikma.com
HIK Technical Analysis
1 New Burlington Place
London,
W1S 2HR
United Kingdom
Phone:
44 20 7399 2760
Officers
| Name | Title |
|---|---|
| Engineer Said Samih Taleb Darwazah | Exec. Chairman & CEO |
| Mr. Mazen Samih Taleb Darwazah | Exec. Vice Chairman & Pres of MENA |
| Mr. Khalid Waleed Hosny Al Nabilsi | Chief Financial Officer |
| Mr. Hussein Arkhagha | Company Sec. & Chief Counsel |
| Mr. Bassam Wael Rushdi Kanaan CFA, CPA | Exec. VP of Corp. Devel. and M&A |
| Ms. Susan Ringdal | Exec. VP of Strategic Planning & Global Affairs |
| Ms. Majda Labadi | Exec. VP of Organisational Devel. |
| Mr. Riad Mishlawi | Pres of Injectables |
| Mr. Brian Hoffmann | Pres of Generics |
| Mr. Samuel Park | Global Head of Intellectual Property (IP) & Gen. Counsel for US |
Exchange: LSE
Country: UK
Currency: Pence sterling (p)
| GIC Sector: | Health Care |
|---|---|
| GIC Group: | Pharmaceuticals, Biotechnology & Life Sciences |
| GIC Industry: | Pharmaceuticals |
| GIC Sub-Industry: | Pharmaceuticals |
| Forward PE: | 9.1491 |
|---|---|
| Trailing PE: | 13.1589 |
| Price-to-Book MRQ: | 1.8829 |
| Price-to-Sales TTM: | 1.2912 |
| IPO Date: | |
| Fiscal Year End: | December |
| Full Time Employees: | 8700 |